3. BioShares Biotechnology Products Fund (BBP)
LifeSci Index Partners’ second ETF is the BioShares Biotechnology Products Fund, which focuses on biotechnology companies with a primary product offering or product candidate that has received U.S. Food and Drug Administration approval.
Unlike BBC and SBIO, this fund invests in primarily larger, more established companies with much clinical trial failure risk behind them. BBP’s portfolio offers exposure to approximately 36 stocks, making it significantly smaller than the two funds mentioned above.
Currently, the fund’s top three holdings are:
• Raptor Pharmaceutical Corp (RPTP)
• Halozyme Therapeutics Inc (HALO)
• Exelixis Inc (EXEL)
4. Validea Market Legends ETF (VALX)
Another ETF newcomer, Validea Funds introduced its Market Legends ETF in December. The actively-managed fund utilizes a proprietary investing system that utilizes the fundamental stock-selection methods outlined by great investors such as Benjamin Graham, Warren Buffett, Martin Zweig, John Neff and many others.
VALX runs 17 different computerized fundamental models as the foundation for the fund’s stock-selection methodology. The top-scoring individual stocks, ranked according to the manager’s best-performing risk-adjusted “guru”-based models, are held within the portfolio. Currently, the fund’s portfolio holds 100 stocks.